The DOI matches its Crossref record.
Favorable Response to Human Adipose Tissue-Derived Mesenchymal Stem Cells in Steroid-Refractory Acute Graft-Versus-Host Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 34
- Weisdorf, 1990, Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome, Blood, 75, 1024, 10.1182/blood.V75.4.1024.1024 · doi:10.1182/blood.v75.4.1024.1024
- Martin, 1991, A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment, Blood, 77, 1821, 10.1182/blood.V77.8.1821.1821 · DOI · Paper page
- Schiller, 1993, Is there an effective therapy for chronic graft-versus-host disease?, Bone Marrow Transplant, 11, 189
- Mookerjee, 1999, Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus, Bone Marrow Transplant, 24, 517, 10.1038/sj.bmt.1701936 · doi:10.1038/sj.bmt.1701936
- Vogelsang, 2001, How I treat chronic graft-versus-host disease, Blood, 97, 1196, 10.1182/blood.V97.5.1196 · doi:10.1182/blood.v97.5.1196
- Lazarus, 1995, Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use, Bone Marrow Transplant, 16, 557
- Koc, 2000, Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy, J Clin Oncol, 18, 307, 10.1200/JCO.2000.18.2.307 · DOI · Paper page
- Horwitz, 2002, Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone, Proc Natl Acad Sci U S A, 99, 8932, 10.1073/pnas.132252399 · DOI · Paper page
- Koc, 2002, Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH), Bone Marrow Transplant, 30, 215, 10.1038/sj.bmt.1703650 · DOI · Paper page
- Puissant, 2005, Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells, Br J Haematol, 129, 118, 10.1111/j.1365-2141.2005.05409.x · DOI · Paper page
- Le Blanc, 2004, Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, 363, 1439, 10.1016/S0140-6736(04)16104-7 · DOI · Paper page
- Fang, 2006, Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells, Bone Marrow Transplant, 38, 389, 10.1038/sj.bmt.1705457 · doi:10.1038/sj.bmt.1705457
- Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825
- Cao, 2005, Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo, Biochem Biophys Res Commun, 332, 370, 10.1016/j.bbrc.2005.04.135 · DOI · Paper page
- Bacigalupo, 1983, High dose bolus methylprednisolone for the treatment of acute graft versus host disease, Blut, 46, 125, 10.1007/BF00320270 · doi:10.1007/bf00320270
- Khoury, 2001, Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin, Bone Marrow Transplant, 27, 1059, 10.1038/sj.bmt.1703032 · doi:10.1038/sj.bmt.1703032
- Wolff, 2005, Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept, Bone Marrow Transplant, 35, 1003, 10.1038/sj.bmt.1704929 · doi:10.1038/sj.bmt.1704929
- Ratanatharathorn, 2003, Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody, Biol Blood Marrow Transplant, 9, 505, 10.1016/S1083-8791(03)00216-7 · doi:10.1016/s1083-8791(03)00216-7
- Lee, 2003, Chronic graft-versus-host disease, Biol Blood Marrow Transplant, 9, 215, 10.1053/bbmt.2003.50026 · DOI · Paper page
- Reyes, 2001, Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells, Blood, 98, 2615, 10.1182/blood.V98.9.2615 · DOI · Paper page
- Fang, 2004, Multipotency of Flk1CD34 progenitors derived from human fetal bone marrow, J Lab Clin Med, 143, 230, 10.1016/j.lab.2003.11.008 · DOI
- Zhao, 2005, Establishment and properties of fetal dermis-derived mesenchymal stem cell lines: plasticity in vitro and hematopoietic protection in vivo, Bone Marrow Transplant, 36, 355, 10.1038/sj.bmt.1705062 · DOI
- Hu, 2003, Isolation and identification of mesenchymal stem cells from human fetal pancreas, J Lab Clin Med, 141, 342, 10.1016/S0022-2143(03)00022-2 · DOI · Paper page
- Chen, 2006, Mesenchymal stem cells in immunoregulation, Immunol Cell Biol, 84, 413, 10.1111/j.1440-1711.2006.01458.x · DOI · Paper page
- Le Blanc, 2005, Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 11, 321, 10.1016/j.bbmt.2005.01.005 · DOI · Paper page
- Bartholomew, 2002, Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo, Exp Hematol, 30, 42, 10.1016/S0301-472X(01)00769-X · DOI · Paper page
- Deng, 2004, Allogeneic bone marrow-derived flk-1+Sca-1− mesenchymal stem cells leads to stable mixed chimerism and donor-specific tolerance, Exp Hematol, 32, 861, 10.1016/j.exphem.2004.06.009 · DOI
- Bensidhoum, 2004, Homing of in vitro expanded Stro-1− or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment, Blood, 103, 3313, 10.1182/blood-2003-04-1121 · DOI · Paper page
- Baudard, 2002, Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients, Bone Marrow Transplant, 30, 287, 10.1038/sj.bmt.1703633 · doi:10.1038/sj.bmt.1703633
- Kim, 2004, Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant, Eur J Haematol, 173, 56, 10.1111/j.1600-0609.2004.00247.x · doi:10.1111/j.1600-0609.2004.00247.x
- Remberger, 2001, Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin, Clin Transplant, 15, 147, 10.1034/j.1399-0012.2001.150301.x · doi:10.1034/j.1399-0012.2001.150301.x
- McCaul, 2000, Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin, J Hematother Stem Cell Res, 9, 367, 10.1089/15258160050079470 · doi:10.1089/15258160050079470
- Przepiorka, 2000, Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease, Blood, 95, 83, 10.1182/blood.V95.1.83 · DOI · Paper page
- Benito, 2001, Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease, Transplantation, 72, 1924, 10.1097/00007890-200112270-00010 · DOI · Paper page
Cited by
Lalu, M. M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B. W., Marshall, J. C., Granton, J., Stewart, D. J., & Canadian Critical Care Trials Group (2012) · PLoS ONE · doi:10.1371/journal.pone.0047559 · Cited by 1,146
Strioga, M., Viswanathan, S., Darinskas, A., Slaby, O., & Michalek, J. (2012) · Stem Cells and Development · doi:10.1089/scd.2011.0722 · Cited by 825
Concise Review: Adipose‐Derived Stem Cells as a Novel Tool for Future Regenerative Medicine
Mizuno, H., Tobita, M., & Uysal, A. C. (2012) · STEM CELLS · doi:10.1002/stem.1076 · Cited by 663
Clinical applications of mesenchymal stem cells
Wang, S., Qu, X., & Zhao, R. C. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-19 · Cited by 483
Self-citationMazini, L., Rochette, L., Amine, M., & Malka, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102523 · Cited by 445
Melief, S. M., Zwaginga, J. J., Fibbe, W. E., & Roelofs, H. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0184 · Cited by 442
The Potential of Adipose Stem Cells in Regenerative Medicine
Lindroos, B., Suuronen, R., & Miettinen, S. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9193-7 · Cited by 441
Zheng, G., Huang, L., Tong, H., Shu, Q., Hu, Y., Ge, M., Deng, K., Zhang, L., Zou, B., Cheng, B., et al. (2014) · Respiratory Research · doi:10.1186/1465-9921-15-39 · Cited by 428
Adipose Tissue-Derived Stem Cells in Regenerative Medicine
Frese, L., Dijkman, P. E., & Hoerstrup, S. P. (2016) · Transfusion Medicine and Hemotherapy · doi:10.1159/000448180 · Cited by 411
Mizuno, H. (2009) · Journal of Nippon Medical School · doi:10.1272/jnms.76.56 · Cited by 349
Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis
Riordan, N. H., Ichim, T. E., Min, W.-P., Wang, H., Solano, F., Lara, F., Alfaro, M., Rodriguez, J. P., Harman, R. J., Patel, A. N., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-29 · Cited by 324
von Bonin, M., Stölzel, F., Goedecke, A., Richter, K., Wuschek, N., Hölig, K., Platzbecker, U., Illmer, T., Schaich, M., Schetelig, J., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.316 · Cited by 306
Adipose‐Derived Stem Cells for Tissue Engineering and Regenerative Medicine Applications
Dai, R., Wang, Z., Samanipour, R., Koo, K.-I., & Kim, K. (2016) · Stem Cells International · doi:10.1155/2016/6737345 · Cited by 301
Adipose stem cells: biology and clinical applications for tissue repair and regeneration
Kokai, L. E., Marra, K., & Rubin, J. P. (2014) · Translational Research · doi:10.1016/j.trsl.2013.11.009 · Cited by 281
Mazini, L., Ezzoubi, M., & Malka, G. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02006-w · Cited by 267
Mesenchymal stem cells for clinical application
Sensebé, L., Krampera, M., Schrezenmeier, H., Bourin, P., & Giordano, R. (2010) · Vox Sanguinis · doi:10.1111/j.1423-0410.2009.01227.x · Cited by 258
Cell Therapy: Types, Regulation, and Clinical Benefits
El-Kadiry, A. E.-H., Rafei, M., & Shammaa, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756029 · Cited by 256
Roemeling-van Rhijn, M., Mensah, F. K. F., Korevaar, S. S., Leijs, M. J., van Osch, G. J. V. M., IJzermans, J. N. M., Betjes, M. G. H., Baan, C. C., Weimar, W., & Hoogduijn, M. J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00203 · Cited by 150
Forbes, S., Bond, A. R., Thirlwell, K. L., Burgoyne, P., Samuel, K., Noble, J., Borthwick, G., Colligan, D., McGowan, N. W. A., Lewis, P. S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5907 · Cited by 54
“Furthermore in certain diseases including graft versus host disease (48-53), critical limb ischemia (54; 55), and acute myocardial infarction (56), allogeneic bmMSCs have been administered with considerable success, although no Phase III trials have been reported.”
Background
Metadata
- Authors
- Fang, B., Song, Y., Liao, L., Zhang, Y., & Zhao, R. C.
- Venue
- Transplantation Proceedings
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 39
- Issue
- 10
- Pages
- 3358-3362
- ISSN
- 0041-1345 (ISSN-L)
- OpenAlex
- W1986142040
- Cited by
- 238
- References
- 0
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.